Brokerages forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce earnings per share of ($1.44) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.40) and the lowest estimate coming in at ($1.50). Adamas Pharmaceuticals reported earnings per share of ($0.72) in the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The company is expected to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($6.04) per share for the current financial year, with EPS estimates ranging from ($6.56) to ($5.67). For the next fiscal year, analysts expect that the firm will post earnings of ($4.03) per share, with EPS estimates ranging from ($4.30) to ($3.84). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same quarter last year, the firm posted ($0.68) EPS. The company’s revenue was up 1435.1% compared to the same quarter last year.
ADMS has been the topic of several research reports. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Friday, February 23rd. William Blair reiterated an “outperform” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, February 21st. Mizuho reiterated a “buy” rating and issued a $48.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, January 23rd. Finally, Piper Jaffray Companies set a $52.00 price objective on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $45.14.
Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new position in shares of Adamas Pharmaceuticals in the fourth quarter valued at about $239,000. Macquarie Group Ltd. grew its stake in shares of Adamas Pharmaceuticals by 18.6% in the fourth quarter. Macquarie Group Ltd. now owns 890,962 shares of the specialty pharmaceutical company’s stock valued at $30,195,000 after acquiring an additional 139,934 shares in the last quarter. Bainco International Investors acquired a new position in shares of Adamas Pharmaceuticals in the fourth quarter valued at about $681,000. Ardsley Advisory Partners acquired a new position in shares of Adamas Pharmaceuticals in the fourth quarter valued at about $5,253,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Adamas Pharmaceuticals in the fourth quarter valued at about $596,000. Hedge funds and other institutional investors own 77.25% of the company’s stock.
Adamas Pharmaceuticals (NASDAQ ADMS) traded up $0.65 during trading hours on Wednesday, hitting $27.10. 2,202,847 shares of the company’s stock traded hands, compared to its average volume of 1,434,034. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $44.00. The firm has a market capitalization of $709.05, a P/E ratio of -6.84 and a beta of 1.59. The company has a debt-to-equity ratio of 1.55, a quick ratio of 10.69 and a current ratio of 10.79.
TRADEMARK VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/zacks-analysts-expect-adamas-pharmaceuticals-inc-adms-to-post-1-44-earnings-per-share.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.